Skip to main content

Table 2 VL suppression over time

From: Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study

 

Months after starting second line

6

12

18

24

30

36

42

48

No of patients in care

252

228

180

146

112

87

72

54

No with VL results

223

197

160

124

97

78

69

45

No with VL <50

159 (71%)

155 (79%)

115 (72%)

97 (78%)

77 (79%)

58 (74%)

48 (70%)

33 (73%)

No with VL <400

195 (87%)

169 (86%)

132 (83%)

107 (86%)

88 (91%)

69 (88%)

60 (87%)

40 (89%)

No with VL ≥1000

22 (10%)

26 (13%)

26 (16%)

16 (13%)

7 (7%)

7 (9%)

2 (3%)

4 (8%)

  1. Note that the 6 monthly VL data reflect a window (e.g. a VL between 9 and 15 months was categorised as a 12 month VL).